Shattuck Labs, Inc. (NASDAQ:STTK) Short Interest Up 21.3% in June

Shattuck Labs, Inc. (NASDAQ:STTK) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 2,171,700 shares, an increase of 21.3% from the May 31st total of 1,790,000 shares. Based on an average trading volume of 331,500 shares, the short-interest ratio is currently 6.6 days. Currently, 5.3% of the company’s shares are sold short.

Analysts Set New Price Targets

A number of equities research analysts have commented on STTK shares. Needham & Company LLC reduced their price objective on Shattuck Labs from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, June 14th. Citigroup reduced their price target on shares of Shattuck Labs from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, June 17th. BTIG Research downgraded shares of Shattuck Labs from a “buy” rating to a “neutral” rating in a report on Monday, June 17th. Finally, HC Wainwright dropped their price objective on shares of Shattuck Labs from $28.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, June 20th.

Insider Activity

In other Shattuck Labs news, CEO Taylor Schreiber bought 14,400 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The stock was acquired at an average price of $3.47 per share, with a total value of $49,968.00. Following the completion of the purchase, the chief executive officer now directly owns 34,502 shares of the company’s stock, valued at approximately $119,721.94. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.50% of the stock is owned by company insiders.

Institutional Trading of Shattuck Labs

A number of large investors have recently added to or reduced their stakes in STTK. Franklin Resources Inc. bought a new position in shares of Shattuck Labs during the 4th quarter valued at approximately $11,663,000. Vanguard Group Inc. increased its position in Shattuck Labs by 38.2% in the first quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock worth $16,270,000 after buying an additional 502,860 shares during the last quarter. Monashee Investment Management LLC bought a new stake in shares of Shattuck Labs in the fourth quarter valued at $713,000. Pinnacle Associates Ltd. lifted its position in shares of Shattuck Labs by 13.9% during the 1st quarter. Pinnacle Associates Ltd. now owns 521,246 shares of the company’s stock valued at $4,660,000 after buying an additional 63,800 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Shattuck Labs during the 4th quarter worth $268,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Trading Up 8.3 %

Shares of Shattuck Labs stock opened at $4.18 on Monday. The stock has a fifty day simple moving average of $7.70 and a 200 day simple moving average of $8.43. The company has a market capitalization of $198.76 million, a P/E ratio of -2.00 and a beta of 1.74. Shattuck Labs has a 12-month low of $1.33 and a 12-month high of $11.76.

Shattuck Labs (NASDAQ:STTK) last released its earnings results on Thursday, May 2nd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.08. Shattuck Labs had a negative return on equity of 64.85% and a negative net margin of 3,133.63%. The company had revenue of $1.15 million during the quarter, compared to analyst estimates of $0.30 million. Shattuck Labs’s quarterly revenue was up 2200.0% on a year-over-year basis. On average, analysts predict that Shattuck Labs will post -1.56 EPS for the current year.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.